Prosecution Insights
Last updated: August 06, 2026
Application No. 18/851,965

X842 FORMULATION

Non-Final OA §112
Filed
Sep 27, 2024
Priority
Mar 30, 2022 — CN PCT/CN2022/084214 +1 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Sinorda Biomedicine Co. Ltd.
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1341 granted / 1581 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-4.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
53 currently pending
Career history
1616
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
16.4%
-23.6% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
44.8%
+4.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1581 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 2 is objected to because of the following informalities: for grammatical reasons, the indefinite article a should appear before the adjective “…polymeric…”. Appropriate correction is required. Claims 8 and 12 are objected to because of the following informalities: for grammatical reasons, the preposition of should appear before the term “…claim 1…”. Appropriate correction is required. Claims 15 and 18 are objected to because of the following informalities: for grammatical reasons, the phrase “…any one of…” should be deleted. Appropriate correction is required. Inventor’s assistance is respectfully requested in correcting any other minor grammatical and/or spelling errors which may be present in the claim set. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5, 10 and 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Claim 5, for instance, recites the broad recitation “…in the range of 40,000-250,000 g/mol…”, and the claim also recites “…preferably [emphasis added] 80,000-150,000 g/mol…” which is the narrower statement of the range/limitation. Analysis of the “preferably” and “more preferably” limitations of claims 10 and 11 is similar. The claims are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claims 6, 9, 11-14, 16, 17, 19 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The phrase "such as" renders the claims indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim 20 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. There is insufficient antecedent basis for the limitation “…the dry weight ratio of disintegrant…” in the claim. Claim 18 is also rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claim depends from an indefinite claim but does not relieve the indefiniteness. Dependent claim 18 is also, therefore, indefinite. Allowable Subject Matter Claims 1 and 7 are allowed. Claims 3 and 4 are objected to as being dependent upon a base claim which has also been objected to, but are otherwise allowable. The subject matter of the remaining claims would be allowable once the objections and 112 rejections outlined above have been overcome. The following is a statement of reasons for the indication of allowable subject matter: Amorphous X842 is the key to the instant invention. US 2022/0002297 A1 (which claims priority to US 63/047,607 filed 7/2/2020), cited in the IDS, appears to be the closest prior art. The reference teaches polymorphs A and B of X842 utilized in pharmaceutical compositions for treating and preventing a gastrointestinal inflammatory disease or a gastric acid related disease (abstract; page 1, column 1, [0002]; page 1, column 2, [0016]ff). The reference explicitly teaches away, in fact, from amorphous forms of X842 due to several undesirable characteristics of non-crystalline forms (page 1, column 1, [0005]). One of ordinary skill in the art, before the effective filing date of the instant invention, would have had no motivation to formulate the instant amorphous form of X842, given the teaching the cited art, in order to arrive at the amorphous X842 formulation and dispersion of the instant invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 7/25/2026
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Jul 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697333
Methods of Treating Splenomegaly
4y 7m to grant Granted Aug 04, 2026
Patent 12691100
NOVEL USE
4y 2m to grant Granted Jul 28, 2026
Patent 12678516
IMMUNOSTIMULATORY TOLL-LIKE RECEPTOR AGONIST-NANOPARTICLE FOR CANCER IMMUNOTHERAPY
2y 9m to grant Granted Jul 14, 2026
Patent 12673026
LIPOSOMAL COMPOSITIONS AND METHODS OF USE THEREOF FOR IMPROVED STABILITY, BIOAVAILABILITY & SUSTAINED RELEASE
2y 1m to grant Granted Jul 07, 2026
Patent 12667560
CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERS
3y 9m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-4.1%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1581 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month